ABTHealthcare · Medical DevicesThe 27 Wall Street analysts covering Abbott Laboratories hold a median 12-month price target of $120 — +10.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 55 of 100 as at 2 Sept 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Abbott Laboratories on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (100): The share price has been relatively steady.
Momentum (26): The shares have been drifting down relative to others.
Size (1): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on ABT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +10.3% from it.
Of the 20 most recent actions, 6 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 25 Aug 2026 | TD Cowen | Maintains | Buy | — |
| 21 Aug 2026 | TD Cowen | Maintains | Buy | $115 → $135 |
| 14 Aug 2026 | Citigroup | Maintains | Buy | — |
| 13 Aug 2026 | Wolfe Research | Upgrade | Outperform | — |
| 13 Aug 2026 | Wolfe Research | Upgrade | Outperform | $130 |
| 28 July 2026 | UBS | Maintains | Buy | $135 → $125 |
| 28 July 2026 | UBS | Maintains | Buy | — |
| 17 July 2026 | BTIG | Maintains | Buy | — |
| 17 July 2026 | BTIG | Maintains | Buy | $131 → $134 |
| 17 July 2026 | Citigroup | Maintains | Buy | $108 → $112 |
| 17 July 2026 | Citigroup | Maintains | Buy | — |
| 17 July 2026 | Evercore ISI Group | Maintains | Outperform | $112 → $120 |
| 17 July 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 17 July 2026 | JP Morgan | Maintains | Overweight | $110 → $120 |
| 17 July 2026 | JP Morgan | Maintains | Overweight | — |
| 17 July 2026 | Piper Sandler | Reiterates | Overweight | $115 → $118 |
| 17 July 2026 | Piper Sandler | Reiterates | Overweight | — |
| 17 July 2026 | RBC Capital | Reiterates | Outperform | $130 |
| 17 July 2026 | RBC Capital | Reiterates | Outperform | — |
| 17 July 2026 | TD Cowen | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ABT appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 3 Sept 2026, Abbott Laboratories returned −15.8% against +21.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 22% of US stocks
Cheaper than 31% of US stocks
Cheaper than 28% of US stocks
Cheaper than 17% of US stocks
Higher than 59% of US stocks
Higher than 11% of US stocks
Higher than 69% of US stocks
Higher than 72% of US stocks
Higher than 73% of US stocks
Higher than 65% of US stocks
Higher than 78% of US stocks
Higher than 51% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Abbott Laboratories has a market value of $188.5B and an enterprise value of $218.7B.
Revenue in the twelve months to 31 Mar 2026: $45.1B. The latest quarter grew 13.0% year on year.
Net income over the same four quarters: $6.3B, a 13.9% net margin.
Diluted earnings per share, trailing twelve months: $3.57.
Free cash flow in the twelve months to 31 Mar 2026: $7.4B, after $2.1B of capital spending.
Abbott Laboratories spent $793.0M on share buybacks and $4.2B on dividends in the twelve months to 31 Mar 2026.
Trailing P/E: 35.3×; forward P/E: 18.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 2.31%, paying out 79% of earnings.
Abbott Laboratories employs 122,000 people — $370K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Abbott Laboratories — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Abbott (ABT) shares closed at $110.47, a +1.41% change from the previous close, and the headline notes the stock exceeded broader market returns on the latest trading day.
Why it matters — An ABT watcher would care because the stock's outperformance relative to the market on this trading day reflects notable price momentum for the company.
The article reports that despite two severe recessions that eliminated dividends across the broader market, a small group of healthcare companies, likely including Abbott, continued raising their payouts in every quarter of both downturns.
Why it matters — For an Abbott watcher, this highlights the stock's dividend resilience through economic downturns, a notable trait for income-focused investors tracking the company.
Abbott Laboratories is embracing the Make America Healthy Again movement by launching a new infant formula made with whole milk, according to Investor's Business Daily. The move positions the company in line with the health-focused movement led by RFK Jr.
Why it matters — This product launch signals Abbott's strategic effort to align its infant nutrition portfolio with a high-profile health movement, which could broaden its appeal with consumers.
Abbott launched Similac 360 Total Care Made With Whole Milk, the first ready-to-feed liquid infant formula made with whole milk in the U.S., priced similarly to its existing powdered Similac formula. The product, available online and at major U.S. retailers, is designed to more closely resemble breast milk with a whole-milk fat blend and five prebiotics.
Why it matters — This launch expands Abbott's infant formula portfolio with a new product category that responds to growing parent interest in whole-milk formulas, potentially broadening its market presence in the U.S.
Zacks Investment Research highlighted Abbott (ABT) as a top momentum stock for the long term, noting that investors can identify strong stocks using the Zacks Style Scores feature of its Premium research service.
Why it matters — Abbott watchers would care because the article positions ABT favorably among momentum stocks, offering a potential reason to keep an eye on it.
The 27 Wall Street analysts covering Abbott Laboratories have a median 12-month price target of $120, with estimates ranging from $103 to $135. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 27 analysts covering Abbott Laboratories, 21 rate it a Buy, 6 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Abbott Laboratories 55 out of 100 across roughly 4,600 US stocks as at 2 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 2 Sept 2026, Abbott Laboratories ranks 55 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (100 of 100).
No one can know that. What the data says: the median 12-month target from 27 analysts implies +10.3% from the last close, and Ticker Nerd's factor model ranks Abbott Laboratories 55 out of 100 as at 2 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Abbott Laboratories publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ABT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $103 to $135 over the next 12 months.
Abbott Laboratories returned -15.8% over the 12 months to 3 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Abbott Laboratories is a global healthcare company that develops, manufactures, and markets a broad range of medical devices, diagnostic systems, nutritional products, and branded generic medicines. Its portfolio spans cardiovascular care, diabetes management, electrophysiology, structural heart, neuromodulation, laboratory diagnostics, point-of-care testing, adult and pediatric nutrition, and established pharmaceuticals for international markets.
The most recent item we track (Zacks Investment Research, 2 Sept 2026): "Abbott (ABT) Exceeds Market Returns: Some Facts to Consider". Abbott (ABT) shares closed at $110.47, a +1.41% change from the previous close, and the headline notes the stock exceeded broader market returns on the latest trading day.
Abbott Laboratories is a global healthcare company that develops, manufactures, and markets a broad range of medical devices, diagnostic systems, nutritional products, and branded generic medicines. Its portfolio spans cardiovascular care, diabetes management, electrophysiology, structural heart, neuromodulation, laboratory diagnostics, point-of-care testing, adult and pediatric nutrition, and established pharmaceuticals for international markets. Abbott serves hospitals, laboratories, healthcare providers, pharmacies, and consumers through products used in chronic disease management, clinical testing, and everyday nutrition. The company plays a significant role in the healthcare market by combining device technology, diagnostics, and nutrition into a diversified platform that supports patient care across multiple settings. Abbott Laboratories is headquartered in Abbott Park, Illinois, and operates with a global commercial footprint across numerous countries.
CEO Mr. Robert B. Ford · 122,000 employees · United States · https://www.abbott.com
